Proteasome inhibitors: Possible novel therapeutic strategy for ischemia-reperfusion injury

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 67-80

  Kandilis, Apostolos N ^a   Karidis, Nikolaos P ^a,b   Kouraklis, Gregory ^a   Patsouris, Efstratios ^a   Vasileiou, Ioanna ^c   Theocharis, Stamatios ^d  

^a UNIVERSITY OF ATHENS   (Greece)

^b FREEMAN HOSPITAL   (United Kingdom)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ischemia reperfusion injury; Ischemic preconditioning; Proteasome inhibitor; Ubiquitin proteasome system

Indexed keywords

(N BENZYLOXYCARBONYL ISOLEUCINE GLUTAMIC ACID(O T BU) ALALEUCINAL; 2 AMINOBENZYLSTATINE; A 6185; AMINO ACID DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPASTATIN; CARFILZOMIB; DELANZOMIB; EPOXOMICIN; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; IXAZOMIB CITRATE; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MG 262; PEPTIDE BENZAMIDE; PEPTIDE VINYL SULFONES; PR 39; PR 924; PR 957; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; SALINOSPORAMIDE A; UBIQUITIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

BRAIN ISCHEMIA; CELL ENERGY; CELL PROTECTION; COLD ISCHEMIA; HUMAN; ISCHEMIC PRECONDITIONING; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SYSTEMATIC REVIEW; UPREGULATION;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; REPERFUSION INJURY; UBIQUITIN;

EID: 84889819611     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.840287     Document Type: Review

References (92)

1. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 2006;3(4):255-61
2. Kukan M. Emerging roles of proteasomes in ischemia-reperfusion injury of organs. J Physiol Pharmacol 2004;55(1 Pt 1):3-15 (Pubitemid 38524210)
3. Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia reperfusion injury. Mediators Inflamm 2010;2010:704202
4. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001;94(6):1133-8 (Pubitemid 32506143)
5. Chamoun F, Burne M, O'Donnell M, Rabb H. Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury. Front Biosci 2000;5:E103-9
6. Arumugam TV, Okun E, Tang SC, et al. Toll-like receptors in ischemia-reperfusion injury. Shock 2009;32(1):4-16
7. Vasileiou I, Kostopanagiotou G, Katsargyris A, et al. Toll-like receptors: a novel target for therapeutic intervention in intestinal and hepatic ischemia-reperfusion injury Expert Opin Ther Targets 2010;14(8):839-53
8. Arumugam TV, Shiels IA, Woodruff TM, et al. The role of the complement system in ischemia-reperfusion injury. Shock 2004;21(5):401-9
9. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007;97(5):738-47 (Pubitemid 46779959)
10. Lopez-Neblina F, Toledo-Pereyra LH. Phosphoregulation of signal transduction pathways in ischemia and reperfusion. J Surg Res 2006;134(2):292-9 (Pubitemid 44092807)
11. Toledo-Pereyra LH, Lopez-Neblina F, Toledo AH. Protein kinases in organ ischemia and reperfusion. J Invest Surg 2008;21(4):215-26 (Pubitemid 352016216)
12. Toledo-Pereyra LH, Toledo AH, Walsh J, Lopez-Neblina F. Molecular signaling pathways in ischemia/reperfusion. Exp Clin Transplant 2004;2(1):174-7
13. Calvey CR, Toledo-Pereyra LH. Selectin inhibitors and their proposed role in ischemia and reperfusion. J Invest Surg 2007;20(2):71-85 (Pubitemid 46680980)
14. Zolk O, Schenke C, Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc Res 2006;70(3):410-21
15. Willis MS, Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006;41(4):567-79 (Pubitemid 44374543)
16. Ciechanover A, Stanhill A. The complexity of recognition of ubiquitinated substrates by the 26S proteasome. Biochim Biophys Acta 2013
17. Navon A, Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 2009;284(49):33713-18
18. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim Biophys Acta 2012;1824(1):3-13
19. Gallastegui N, Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem Sci 2010;35(11):634-42
20. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) 2003;81(4):235-45 (Pubitemid 36578922)
21. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82(2):373-428 (Pubitemid 34654457)
22. Huber EM, Groll M. Inhibitors for the immuno-and constitutive proteasome: current and future trends in drug development. Angewandte Chemie (International ed in English) 2012;51(35):8708-20
23. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006;281(13):8582-90 (Pubitemid 43847961)
24. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21(4):245-73 (Pubitemid 32565494)
25. de Bettignies G, Coux O. Proteasome inhibitors: dozens of molecules and still counting. Biochimie 2010;92(11):1530-45
26. Yu X, Kem DC. Proteasome inhibition during myocardial infarction. Cardiovasc Res 2010;85(2):312-20
27. Wu WK, Cho CH, Lee CW, et al. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett 2010;293(1):15-22
28. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011;5(2):101-10
29. Grawert MA, Groll M. Exploiting nature's rich source of proteasome inhibitors as starting points in drug development. Chem Commun (Camb) 2011
30. Basler M, Dajee M, Moll C, et al. Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol (Baltimore, Md: 1950) 2010;185(1):634-41
31. Singh AV, Bandi M, Aujay MA, et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011;152(2):155-63
32. Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116(5):637-46 (Pubitemid 34453203)
33. Xie P, Guo S, Fan Y, et al. Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. J Biol Chem 2009;284(9):5488-96
34. Costa VM, Silva R, Ferreira R, et al. Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. Toxicology 2009;257(1-2):70-9
35. Pedrozo Z, Sanchez G, Torrealba N, et al. Calpains and proteasomes mediate degradation of ryanodine receptors in a model of cardiac ischemic reperfusion. Biochim Biophy Acta 2010;1802(3):356-62
36. Tanaka H, Miake J, Notsu T, et al. Proteasomal degradation of Kir6.2 channel protein and its inhibition by a Na+ channel blocker aprindine. Biochem Biophys Res Commun 2005;331(4):1001-6 (Pubitemid 40692460)
37. Takagi H, Hsu CP, Kajimoto K, et al. Activation of PKN mediates survival of cardiac myocytes in the heart during ischemia/reperfusion. Circ Res 2010;107(5):642-9
38. Marfella R, Di Filippo C, Portoghese M, et al. The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol 2009;18(6):332-45
39. Huang S, Patterson E, Yu X, et al. Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol 2008;294(3):H1298-303 (Pubitemid 351468727)
40. Dosenko VE, Nagibin VS, Tumanovskaya LV, et al. Proteasomal proteolysis in anoxia-reoxygenation, preconditioning and postconditioning of isolated cardiomyocytes. Pathophysiology 2006;13(2):119-25
41. Surova OV, Nagibin VS, Tumanovskaya LV, et al. Effect of a low dose of proteasome inhibitor on cell death and gene expression in neonatal rat cardiomyocyte cultures exposed to anoxia-reoxygenation. Exp Clin Cardiol 2009;14(2):e57-61
42. Moss NC, Tang RH, Willis M, et al. Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg 2008;136(5):1274-9
43. Stansfield WE, Moss NC, Willis MS, et al. Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury. Ann Thorac Surg 2007;84(1):120-5 (Pubitemid 46921115)
44. Pye J, Ardeshirpour F, McCain A, et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003;284(3):H919-26 (Pubitemid 36228240)
45. Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999;31(2):467-76 (Pubitemid 29089894)
46. Gao Y, Lecker S, Post MJ, et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Investig 2000;106(3):439-48 (Pubitemid 30655644)
47. Bao J, Sato K, Li M, et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol 2001;281(6):H2612-18
48. Hoffmeyer MR, Scalia R, Ross CR, et al. PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2000;279(6):H2824-8 (Pubitemid 32005871)
49. Hicks M, Hing A, Gao L, et al. Organ preservation. Methods Mol Biol 2006;333:331-74
50. Majetschak M, Patel MB, Sorell LT, et al. Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem Biophys Res Commun 2008;365(4):882-8 (Pubitemid 350234876)
51. Baker TA, Geng Q, Romero J, et al. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochem Biophys Res Commun 2010;401(4):548-53
52. Geng Q, Romero J, Saini V, et al. A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem Biophys Res Commun 2009;390(4):1136-41
53. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003;83(4):1113-51 (Pubitemid 37222269)
54. Cai Z, Semenza GL. PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 2005;97(12):1351-9
55. Nagoshi T, Matsui T, Aoyama T, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 2005;115(8):2128-38 (Pubitemid 41134154)
56. Bulvik BE, Berenshtein E, Meyron-Holtz EG, et al. Cardiac protection by preconditioning is generated via an iron-signal created by proteasomal degradation of iron proteins. PLoS One 2012;7(11):e48947
57. Divald A, Kivity S, Wang P, et al. Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 2010;106(12):1829-38
58. Churchill EN, Ferreira JC, Brum PC, et al. Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res 2010;85(2):385-94
59. Asai M, Tsukamoto O, Minamino T, et al. PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts. J Mol Cell Cardiol 2009;46(4):452-62
60. Keller JN, Huang FF, Zhu H, et al. Oxidative stress-associated impairment of proteasome activity during ischemia-reperfusion injury. J Cereb Blood Flow Metab 2000;20(10):1467-73
61. Di Napoli M, McLaughlin B. The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors. Curr Opin Investig Drugs (London, England: 2000) 2005;6(7):686-99 (Pubitemid 40904039)
62. Buchan AM, Li H, Blackburn B. Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation. Neuroreport 2000;11(2):427-30 (Pubitemid 30074663)
63. Henninger N, Sicard KM, Bouley J, et al. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 2006;398(3):300-5 (Pubitemid 43673703)
64. Williams AJ, Dave JR, Tortella FC. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 2006;49(2):106-12 (Pubitemid 44172911)
65. Phillips JB, Williams AJ, Adams J, et al. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000;31(7):1686-93 (Pubitemid 30437524)
66. Williams AJ, Berti R, Dave JR, et al. Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519. Stroke 2004;35(5):1186-91 (Pubitemid 38543541)
67. Doeppner TR, Mlynarczuk-Bialy I, Kuckelkorn U, et al. The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis. Brain 2012;135(Pt 11):3282-97
68. Rehni AK, Singh TG, Behl N, Arora S. Possible involvement of ubiquitin proteasome system and other proteases in acute and delayed aspects of ischemic preconditioning of brain in mice. Biol Pharm Bull 2010;33(12):1953-7
69. Legrand M, Mik EG, Johannes T, et al. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med 2008;14(7-8):502-16
70. Snoeijs MG, van Heurn LW, Buurman WA. Biological modulation of renal ischemia-reperfusion injury. Curr Opin Organ Transplant 2010;15(2):190-9
71. Huber JM, Tagwerker A, Heininger D, et al. The proteasome inhibitor bortezomib aggravates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009;297(2):F451-60
72. Takaoka M, Itoh M, Hayashi S, et al. Proteasome participates in the pathogenesis of ischemic acute renal failure in rats. Eur J Pharmacol 1999;384(1):43-6
73. Takaoka M, Itoh M, Kohyama S, et al. Proteasome inhibition attenuates renal endothelin-1 production and the development of ischemic acute renal failure in rats. J Cardiovasc Pharmacol 2000;36(5 Suppl 1):S225-7
74. Itoh M, Takaoka M, Shibata A, et al. Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats. J Pharmacol Exp Ther 2001;298(2):501-7 (Pubitemid 32673400)
75. Cho EH, Koh PO. Proteomic identification of proteins differentially expressed by melatonin in hepatic ischemia-reperfusion injury. J Pineal Res 2010;49(4):349-55
76. Huber N, Sakai N, Eismann T, et al. Age-related decrease in proteasome expression contributes to defective nuclear factor-kappaB activation during hepatic ischemia/reperfusion. Hepatology 2009;49(5):1718-28
77. Alexandrova A, Petrov L, Georgieva A, et al. Effect of MG132 on proteasome activity and prooxidant/antioxidant status of rat liver subjected to ischemia/reperfusion injury. Hepatol Res 2008;38(4):393-401 (Pubitemid 351321182)
78. Padrissa-Altés S, Zaouali MA, Boncompagni E, et al. The use of a reversible proteasome inhibitor in a model of reduced-size orthotopic liver transplantation in rats. Exp Mol Pathol 2012;93(1):99-110
79. Zaouali MA, Bardag-Gorce F, Carbonell T, et al. Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Pathol 2013;94(2):352-9
80. Tian XF, Zhang XS, Li YH, et al. Proteasome inhibition attenuates lung injury induced by intestinal ischemia reperfusion in rats. Life Sci 2006;79(22):2069-76
81. Yao JH, Li YH, Wang ZZ, et al. Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion. Clin Exp Pharmacol Physiol 2007;34(11):1102-8
82. Jing H, Shen G, Wang G, et al. MG132 alleviates liver injury induced by intestinal ischemia/reperfusion in rats: involvement of the AhR and NFkappaB pathways. J Surg Res 2012;176(1):63-73
83. Park JW, Qi WN, Cai Y, et al. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. Plast Reconstr Surg 2007;120(7):1808-18 (Pubitemid 350306675)
84. Park JW, Kim KM, Oh KJ, et al. Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury. J Trauma 2009;66(3):743-8
85. Wang J, Jiang S, Kwong JM, et al. Nuclear factor-kappaB p65 and upregulation of interleukin-6 in retinal ischemia/reperfusion injury in rats. Brain Res 2006;1081(1):211-18
86. Fierabracci A. Proteasome inhibitors: a new perspective for treating autoimmune diseases. Curr Drug Targets 2012;13(13):1665-75
87. Broyl A, Jongen JL, Sonneveld P. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Semin Hematol 2012;49(3):249-57
88. Powell SR, Divald A. The ubiquitin-proteasome system in myocardial ischaemia and preconditioning. Cardiovasc Res 2010;85(2):303-11
89. Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: poisons and remedies. Med Res Rev 2008;28(2):309-27 (Pubitemid 351281191)
90. Kloss A, Meiners S, Ludwig A, Dahlmann B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 2010;85(2):367-75
91. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62(17):4996-5000 (Pubitemid 34984425)
92. Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11(3):239-53